India’s pharmaceutical journey is often cited as one of the most remarkable examples of policy-driven industrial success. A pivotal moment came in 1959, when Justice N Rajagopala Ayyangar recommended a shift toward process patents rather than product patents for medicines. This approach, later enshrined in the Patents Act 1970, allowed Indian firms to manufacture drugs using alternative processes without infringing on foreign patents. The result was transformative. India emerged as a global leader in generic medicines, supplying affordable drugs to over 200 countries and accounting for a significant share of global generic consumption.However, the policy landscape that once enabled this growth is now presenting new challenges. As India aspires to move beyond generics and become a hub for innovation and new drug discovery, the tension between affordability and profitability has become increasingly pronounced. Central to this debate is the Drugs Price Control Order 2013, which regulates the prices of essential medicines through ceilings set by the National Pharmaceutical Pricing Authority.The evolution of price control policies reflects shifting priorities. Earlier versions of the DPCO focused on bulk drugs, but the 2013 framework marked a structural shift toward controlling formulations, with prices determined by averaging market rates. Today, hundreds of medicines fall under price control, guided by the National List of Essential Medicines 2022. While this has undeniably improved access and affordability, it has also introduced economic constraints for pharmaceutical companies.Developing even a complex generic drug now requires substantial investment, often ranging between $25 million and $30 million. These costs include clinical studies, regulatory compliance, and manufacturing readiness for both domestic and international markets. Yet, the financial returns are far from guaranteed. Many projects fail before reaching the market, and those that succeed operate within limited commercial windows before competition erodes profits. The economics are inherently risky, with gains concentrated in a small fraction of successful outcomes.When price controls are introduced or expanded, the financial equation becomes even more precarious. A reduction in expected revenues, even by a modest percentage, can significantly lower the overall viability of a project. The impact is not linear; it disproportionately affects the potential upside that justifies initial investment. Shortening the effective market period, whether through regulatory interventions or competitive pressures, further compounds the problem by reducing the time available to recover development costs.This creates a structural dilemma. India’s ambition to transition from a generic powerhouse to an innovation-driven pharmaceutical hub requires sustained investment in research and development. Yet, such investment is largely funded by profits generated from the generics business. When pricing regulations compress margins, they inadvertently limit the resources available for future innovation.The irony is striking. The original intent of India’s patent policy was to curb foreign monopolies and nurture domestic industry. Today, aggressive price control measures risk constraining that very industry’s ability to evolve. The balance between ensuring affordable medicines and fostering innovation is delicate, and policy decisions must carefully consider their long-term implications.India’s global reputation as the “pharmacy of the world” rests on its ability to deliver affordable medicines at scale.
